Anti‐VEGF vs steroids: BCVA: gain of 15 or more ETDRS letters
Anti‐VEGF leads to higher gain of 15 letters or more of visual acuity compared with steroid (high certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐VEGF vs steroid Gain of 15 letters or more of visual acuity · people with BRVO Anti‐VEGF leads to higher gain of 15 letters or more of visual acuity compared with steroid (high certainty). Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion (2020) · Cochrane Headline outcomes only | RR 1.67 [1.33, 2.1] | 2 studies · 330 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.